KLHL6

KLHL6 is a BTB-Kelch protein that serves as the substrate-recognition adapter of a Cullin3-RING E3 ubiquitin ligase, coupling antigen-receptor signaling to targeted proteasomal degradation in lymphocytes (PMID:28807996, PMID:29695787). It binds the N-terminal domain of Cullin3, which stabilizes KLHL6 and promotes its assembly into a homomultimeric ligase scaffold (PMID:37286065). Through this complex KLHL6 ubiquitinates a set of substrates that tune B-cell and T-cell physiology: in B cells it is required for BCR-induced PLCγ2 activation, Ca2+ flux, proliferation, and germinal center formation (PMID:16166635), and it controls surface BCR homeostasis by degrading the signaling subunits CD79A and CD79B (PMID:38630892); it also degrades the mRNA decay factor Roquin2 in a BCR-triggered, Roquin2-Tyr691-dependent manner, thereby relieving Roquin2-mediated decay of the NF-κB inhibitor A20/TNFAIP3 (PMID:29695787). In CD8+ T cells KLHL6 restrains exhaustion by driving poly-ubiquitination and degradation of TOX and preserves mitochondrial fitness by limiting fission through post-translational control of the PGAM5–Drp1 axis, with KLHL6 itself downregulated by TCR-driven PI3K-AKT inhibition of FOXO1 (PMID:41535474). Cancer-associated and domain-specific mutations alter KLHL6 function: lesions disrupting Cullin3 interaction abrogate ligase activity (PMID:29695787), while BTB-domain mutations perturb localization and homodimerization to raise surface BCR signaling and Kelch-domain mutations have the opposite effect (PMID:38630892).

1. 2005 High

   Established that KLHL6 is a B-cell-intrinsic requirement for antigen-receptor signaling, placing it upstream of the BCR signal-transduction machinery before any molecular activity was known.

   Evidence Conditional and global knockout mice with BCR cross-linking assays measuring proliferation, Ca2+ flux, and PLCγ2 activation

   PMID:16166635

   Open questions at the time

   • Molecular activity of KLHL6 unknown at this stage
   • No substrate or biochemical mechanism linking KLHL6 to PLCγ2/Ca2+ identified
   • Does not explain whether the defect is signaling-proximal or receptor-level
2. 2017 Medium

   Identified KLHL6 as a Cullin3 binding partner, providing the first molecular rationale that it acts as a CUL3-RING ligase substrate adapter rather than a passive signaling scaffold.

   Evidence Co-immunoprecipitation in BL2 Burkitt's lymphoma cells, with reported HBXIP/Lamtor5 binding

   PMID:28807996

   Open questions at the time

   • Co-IP in a single cell line without reciprocal validation
   • No substrate identified
   • Functional consequence of HBXIP/Lamtor5 binding not defined
3. 2018 High

   Demonstrated a functional CUL3-KLHL6 ligase and named its first substrate, connecting KLHL6 ubiquitination activity to NF-κB control and DLBCL biology.

   Evidence Co-IP, in vitro ubiquitination assays, Roquin2 Y691F mutagenesis, and xenograft models

   PMID:29695787

   Open questions at the time

   • Whether Roquin2 is the only relevant substrate in B cells unaddressed
   • Structural basis of substrate recognition not resolved
   • Link between this axis and the earlier PLCγ2/Ca2+ phenotype not directly tested
4. 2023 Medium

   Provided biophysical evidence that KLHL6 self-assembles into a homomultimer and that Cullin3-NTD binding stabilizes it, supporting a stoichiometric scaffold role in the ligase.

   Evidence Recombinant SUMO-tagged protein, gel filtration, negative-stain EM, and reconstitution with Cul3NTD

   PMID:37286065

   Open questions at the time

   • No high-resolution structure
   • No functional mutagenesis tying multimerization to ligase activity
   • Substrate engagement not captured in the reconstituted assembly
5. 2024 High

   Identified CD79A/CD79B as KLHL6 degradation targets and dissected domain-specific mutation effects, explaining how KLHL6 sets surface BCR levels and how mutations rewire signaling.

   Evidence Interactome screens, loss-of-function experiments, surface BCR quantification, and BTB vs Kelch domain mutagenesis in DLBCL contexts

   PMID:38630892

   Open questions at the time

   • Stoichiometry of CD79A vs CD79B targeting unresolved
   • How localization changes mechanistically alter substrate access not defined
   • Relationship between CD79A/B degradation and Roquin2 axis not integrated
6. 2026 High

   Extended KLHL6 function to CD8+ T cells, showing dual control of exhaustion (via TOX degradation) and mitochondrial fission (via the PGAM5-Drp1 axis), and identifying TCR-PI3K-AKT-FOXO1 as the regulatory input that suppresses KLHL6.

   Evidence In vivo CRISPR screens, enforced KLHL6 expression, TOX ubiquitination assays, mitochondrial fission readouts, and tumor/viral infection models

   PMID:41535474

   Open questions at the time

   • Whether PGAM5 is a direct ubiquitination substrate vs an indirect target not fully resolved
   • Mechanism coupling FOXO1 to KLHL6 transcription not detailed
   • Interplay between TOX and mitochondrial arms within the same cell unclear
7. 2026 Low

   Reported CDK2 as a drug-inducible KLHL6 degradation target in AML, suggesting a role in myeloid differentiation beyond lymphocytes.

   Evidence Co-IP, Western blot for CDK2 levels, flow cytometry, and an in vivo AML mouse model under loganetin treatment

   PMID:42227424

   Open questions at the time

   • Single Co-IP without reciprocal validation or ubiquitination reconstitution
   • No mutagenesis confirming direct CUL3-KLHL6-dependent CDK2 degradation
   • Specificity of loganetin-induced CDK2 loss to KLHL6 not established

• How a single substrate-recognition adapter selects among Roquin2, CD79A/B, TOX, PGAM5, and CDK2 in different cell types and signaling states remains unresolved.
• No structural model of substrate degron recognition by the Kelch domain
• Rules governing cell-type-specific substrate choice unknown
• Whether all reported substrates are direct CUL3-KLHL6 targets not uniformly confirmed